GCG and type 2 diabetes mellitus: In a phase 2b randomized trial involving adults with type 2 diabetes, cotadutide—another glucagon/GLP-1 receptor agonist—demonstrated significant improvements in glycemic control and body weight, compared to placebo (p < 0.001 for all measures).